Every material Form 8-K ASP Isotopes Inc. has filed with the SEC since October 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
ASP Isotopes disclosed that Tetra4, a subsidiary of Renergen Limited, has completed commissioning and achieved stable liquid helium production at the Virginia Gas Project in South Africa. The filing reports no revenue or financial results, and the company said it is ramping toward nameplate capacity, which it expects to reach during the fourth quarter of 2026. For shareholders, this is an operational step toward initial deliveries, but the filing does not quantify its financial effect.
Tetra4 completed commissioning and achieved stable liquid helium production, announced October 26, 2026.
Liquid helium is accumulating in cryogenic storage ahead of initial deliveries under existing offtake agreements.
The company expects Renergen's nameplate capacity to be reached during the fourth quarter of 2026.
Phase 1 is expected to produce approximately 70 Mcf/day of liquid helium and approximately 2,500 GJ/day of LNG.
Quantum Leap Energy, a wholly owned subsidiary of ASP Isotopes, signed a Heads of Agreement with South Africa's Nuclear Energy Corporation (Necsa) that sets a binding commercial framework for a joint venture to produce High-Assay Low-Enriched Uranium at Necsa's Pelindaba site. The filing gives no financial value or capital commitment for the venture, so its effect on shareholders is not quantified.
QLE would hold approximately 80% of the joint venture and lead operations and capital arrangements; Necsa would hold approximately 20%.
The joint venture would develop, finance, construct, commission, own and operate a test bench and commercial-scale HALEU facility at Pelindaba, South Africa.
QLE has offtake for the expected HALEU output through supply agreements with TerraPower.
South Africa's Ministry of Electricity and Energy approved QLE's source material and equipment activities at Pelindaba in July 2026.
ASP Isotopes disclosed that on October 2, 2026, ENDRA Life Sciences filed a Registration Statement on Form S-4 for the previously announced merger involving Noble Africa and Renergen. The merger remains subject to closing conditions, including approval by ENDRA stockholders, so shareholders should expect the transaction's outcome to depend on those steps.
Merger Agreement entered into on June 25, 2026, among ENDRA, ASP Isotopes, Noble Africa, Renergen and Kruger Merger Sub LLC
On October 2, 2026, ENDRA filed a Form S-4 Registration Statement containing a proxy statement and prospectus
Under the agreement, Merger Sub would merge with and into Noble Africa, which would survive as a wholly owned subsidiary of ENDRA
Closing is subject to conditions, including timely approval of the merger by ENDRA stockholders, if obtained at all
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ASP Isotopes Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →